Meeting
2021 ASCO Annual Meeting
BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.
Authors
Olivier Jules van Not
University Medical Center Utrecht, Leiden, Netherlands
Olivier Jules van Not , Alfonsus Johannes Maria van den Eertwegh , John B. A. G. Haanen , Christian U. Blank , Maureen J.B. Aarts , Franchette van den Berkmortel , Jan Willem de Groot , Geke Hospers , Ellen Kapiteijn , Djura Piersma , Rozemarijn Van Rijn , Marion Stevense , Astrid Aplonia Maria Van Der Veldt , Gerard Vreugdenhil , Marye Boers-Sonderen , Han J. Bonenkamp , Anne M.L. Jansen , Willeke Blokx , Michel W.J.M. Wouters , Karijn Suijkerbuijk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9558)
DOI
10.1200/JCO.2021.39.15_suppl.9558
Abstract #
9558
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
First Author: Joanna Mangana
Poster
2021 ASCO Annual Meeting
Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.
First Author: B. Adi Kartolo
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.
First Author: Lydia Gaba
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Retrospective study comparing survival when ipilimimab used with and without radiotherapy in patients with advanced melanoma.
First Author: Dominique Siobhan Parslow